Literature DB >> 18922979

Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.

Thomas R Johnson1, Lakshmipathi Khandrika, Binod Kumar, Sarah Venezia, Sweaty Koul, Ryan Chandhoke, Paul Maroni, Robert Donohue, Randall B Meacham, Hari K Koul.   

Abstract

Overexpression of focal adhesion kinase (FAK) has been well correlated with tumor development and/or the maintenance of tumor phenotype. In addition, inappropriate activation of the extracellular regulated kinase (ERK) signaling pathway is common to many human cancers. In the present study, we investigated the interplay between FAK and ERK in androgen-independent prostate cancer cells (PC3 and DU145 cells). We observed that suppression of FAK expression using small interfering RNA-mediated knockdown decreased the clonogenic activity, whereas overexpression of FAK increased it. We also observed that detachment of PC3 and DU145 cells from their substrate induced tyrosine phosphorylation of FAK. ERK knockdown diminished FAK protein levels and tyrosine phosphorylation of FAK as well as FAK promoter-reporter activity. We also tested the effect of MEK inhibitors and small interfering RNA-mediated knockdown of ERK1 and/or ERK2 on cell proliferation, invasiveness, and growth in soft agar of PC3 and DU145 cells. Inhibition of ERK signaling grossly impaired clonogenicity as well as invasion through Matrigel. However, inhibition of ERK signaling resulted in only a modest inhibition of 3H-thymidine incorporation and no effect on overall viability of the cells or increased sensitivity to anoikis. Taken together, these data show, for the first time, a requirement for FAK in aggressive phenotype of prostate cancer cells; reveal interdependence of FAK and ERK1/2 for clonogenic and invasive activity of androgen-independent prostate cancer cells; suggest a role for ERK regulation of FAK in substrate-dependent survival; and show for the first time, in any cell type, the regulation of FAK expression by ERK signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922979     DOI: 10.1158/1541-7786.MCR-08-0052

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  24 in total

1.  A novel dysregulated pathway-identification analysis based on global influence of within-pathway effects and crosstalk between pathways.

Authors:  Junwei Han; Chunquan Li; Haixiu Yang; Yanjun Xu; Chunlong Zhang; Jiquan Ma; Xinrui Shi; Wei Liu; Desi Shang; Qianlan Yao; Yunpeng Zhang; Fei Su; Li Feng; Xia Li
Journal:  J R Soc Interface       Date:  2015-01-06       Impact factor: 4.118

2.  ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Authors:  Dannah R Miller; Matthew A Ingersoll; Ming-Fong Lin
Journal:  Endocr Relat Cancer       Date:  2019-04-01       Impact factor: 5.678

3.  Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Authors:  Zhihu Ding; Chang-Jiun Wu; Mariela Jaskelioff; Elena Ivanova; Maria Kost-Alimova; Alexei Protopopov; Gerald C Chu; Guocan Wang; Xin Lu; Emma S Labrot; Jian Hu; Wei Wang; Yonghong Xiao; Hailei Zhang; Jianhua Zhang; Jingfang Zhang; Boyi Gan; Samuel R Perry; Shan Jiang; Liren Li; James W Horner; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Cell       Date:  2012-02-16       Impact factor: 41.582

4.  Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion.

Authors:  Katerina Kouvidi; Aikaterini Berdiaki; Dragana Nikitovic; Pavlos Katonis; Nikos Afratis; Vincent C Hascall; Nikos K Karamanos; George N Tzanakakis
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

Review 5.  Anoikis mediators in oral squamous cell carcinoma.

Authors:  J Bunek; P Kamarajan; Y L Kapila
Journal:  Oral Dis       Date:  2010-11-29       Impact factor: 3.511

6.  Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.

Authors:  Tsung-Chieh Shih; Ruiwu Liu; Chun-Te Wu; Xiaocen Li; Wenwu Xiao; Xiaojun Deng; Sophie Kiss; Ting Wang; Xiao-Jia Chen; Randy Carney; Hsing-Jien Kung; Yong Duan; Paramita M Ghosh; Kit S Lam
Journal:  Clin Cancer Res       Date:  2018-04-17       Impact factor: 12.531

7.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.

Authors:  Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

8.  The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells.

Authors:  Mintu Pal; Sweaty Koul; Hari K Koul
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

9.  Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.

Authors:  Haihao Sun; Stephen Pisle; Erin R Gardner; William D Figg
Journal:  Cancer Biol Ther       Date:  2010-07-09       Impact factor: 4.742

10.  MEK5/ERK5 signaling modulates endothelial cell migration and focal contact turnover.

Authors:  Désirée Spiering; Mirco Schmolke; Nils Ohnesorge; Marc Schmidt; Matthias Goebeler; Joachim Wegener; Viktor Wixler; Stephan Ludwig
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.